Experimental drug shows potential to alleviate eczema
Summary
Trinity College scientist Professor Luke O'Neill discusses a promising new eczema drug developed by his company, Citrix. The experimental tablet targets the PKM2 protein to reduce inflammation and itching, showing significant benefits in a recent clinical trial led by dermatologist Alan Irvine. O'Neill explains that the discovery began in his lab by studying the fundamental mechanisms of inflammation before selecting eczema as a target due to high patient need. While the drug shows huge commercial potential, further testing is required before it can reach the market, with Citrix planning ad…
Topics discussed
Introduction to Professor Luke O'Neill and eczema drug
Overview of the clinical trial and its origins
Explanation of the drug's mechanism and key researchers
Patient benefits: relief from itch and inflammation
Challenges of drug development and investment
Commercial potential and market outlook
Timeline for market release and trial leadership
Discussion on the discovery process and approach
Future applications beyond eczema
Closing remarks and promotion of other podcasts
Listen ad-free on Castria